FindTrial
Sign In

Optimizing Blood Conservation in THA: A Synergistic Strategy of Medium-Dose Preoperative TXA Outperforms Mere Dose Escalation and is Confounded by Drain Use

Optimizing Blood Conservation in THA: A Synergistic Strategy of Medium-Dose Preoperative TXA Outperforms Mere Dose Escalation and is Confounded by Drain Use

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110397
Enrollment
Unknown
Registered
2025-10-13
Start date
2025-10-13
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total hip arthroplasty

Interventions

No-TXA:None
Low-dose TXA:None
Medium-dose TXA:None
High-dose TXA:None

Sponsors

Yuyao Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 95 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : ( 1 ) unilateral primary cementless total hip arthroplasty ; ( 2 ) The surgical method was posterolateral approach ; ( 3 ) Only TXA was used as an anti-fibrinolytic drug during the perioperative period.

Exclusion criteria

Exclusion criteria: Exclusion criteria : ( 1 ) bilateral total hip arthroplasty ; ( 2 ) Incomplete imaging or clinical data ; ( 3 ) The follow-up time was less than 1 month ; ( 4 ) Hip revision surgery.

Design outcomes

Primary

MeasureTime frame
Total blood loss;Visible blood loss;Hidden blood loss;Hb decline level;Transfusion rate;—

Secondary

MeasureTime frame
DVT/PE rate;—

Countries

China

Contacts

Public ContactQiyuan Lu

Yuyao Hospital of Traditional Chinese Medicine

2227059714@qq.com+86 159 9005 5949

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026